TY - JOUR AU - Szabó, Diána AU - Janovák, László AU - Abdelghafour, Mohamed M. AU - Takács, Tamás AU - Csanády, Miklós ifj. AU - Spengler, Gabriella AU - Szakács, László AU - Csanády, Miklós AU - Rovó, László TI - Új minimálinvazív kezelési lehetőségek jó- és rosszindulatú fül-orr-gégészeti betegségekben nanoszerkezetű hatóanyag-leadó rendszerek alkalmazásával = New minimally invasive treatment options in benign and malignant otorhinolaryngological diseases using nanostructured drug delivery systems JF - ORVOSI HETILAP J2 - ORV HETIL VL - 165 PY - 2024 IS - 10 SP - 370 EP - 378 PG - 9 SN - 0030-6002 DO - 10.1556/650.2024.32978 UR - https://m2.mtmt.hu/api/publication/34729015 ID - 34729015 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Juhász, Márk Félix AU - Tóháti, Rebeka AU - Jászai, Viktória Adrienn AU - Molnár, Regina AU - Borbásné Farkas, Kornélia AU - Czakó, László AU - Vincze, Áron AU - Erőss, Bálint Mihály AU - Szentesi, Andrea Ildikó AU - Izbéki, Ferenc AU - Papp, Mária AU - Hegyi, Péter AU - Párniczky, Andrea ED - Váncsa, Szilárd / Collaborator ED - Márta, Katalin / Collaborator ED - Földi, Mária / Collaborator ED - Nagy, Rita / Collaborator ED - Hegyi, Péter Jenő / Collaborator ED - Ocskay, Klementina / Collaborator ED - Imrei, Marcell / Collaborator ED - Mikó, Alexandra / Collaborator ED - Gódi, Szilárd / Collaborator ED - Bajor, Judit / Collaborator ED - Hágendorn, Roland / Collaborator ED - Sarlós, Patrícia / Collaborator ED - Szabó, Imre / Collaborator ED - Czimmer, József / Collaborator ED - Faluhelyi, Nándor / Collaborator ED - Kanizsai, Péter / Collaborator ED - Nagy, Tamás / Collaborator ED - Gajdán, László / Collaborator ED - Kui, Balázs / Collaborator ED - Illés, Dóra / Collaborator ED - Takács, Tamás / Collaborator ED - Vitális, Zsuzsanna / Collaborator ED - Hamvas, József / Collaborator ED - Varga, Márta / Collaborator ED - Bod, Barnabás / Collaborator ED - Novák, János / Collaborator ED - Maurovich-Horvat, Pál / Collaborator ED - Doros, Attila / Collaborator ED - Deák, Pál Ákos / Collaborator ED - Varga, Csaba / Collaborator ED - Gaál, Szabolcs / Collaborator ED - Zubek, László / Collaborator ED - Gál, János / Collaborator ED - Lázár, Balázs / Collaborator ED - Hussein, Tamás / Collaborator ED - Kovács, Bea / Collaborator ED - Tarján, Dorottya / Collaborator ED - Lipp, Mónika Bernadett / Collaborator ED - Urbán, Orsolya / Collaborator ED - Tornai, Tamás / Collaborator TI - Invalidity of Tokyo guidelines in acute biliary pancreatitis : A multicenter cohort analysis of 944 pancreatitis cases JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - 8 SP - 767 EP - 774 PG - 8 SN - 2050-6406 DO - 10.1002/ueg2.12402 UR - https://m2.mtmt.hu/api/publication/34072590 ID - 34072590 N1 - * Megosztott szerzőség AB - There is a noteworthy overlap between the clinical picture of biliary acute pancreatitis (AP) and the 2018 Tokyo guidelines currently used for the diagnosis of cholangitis (AC) and cholecystitis (CC). This can lead to significant antibiotic and endoscopic retrograde cholangiopancreatography (ERCP) overuse.We aimed to assess the on-admission prevalence of AC/CC according to the 2018 Tokyo guidelines (TG18) in a cohort of biliary AP patients, and its association with antibiotic use, ERCP and clinically relevant endpoints.We conducted a secondary analysis of the Hungarian Pancreatic Study Group's prospective multicenter registry of 2195 AP cases. We grouped and compared biliary cases (n = 944) based on the on-admission fulfillment of definite AC/CC according to TG18. Aside from antibiotic use, we evaluated mortality, AC/CC/AP severity, ERCP performance and length of hospitalization. We also conducted a literature review discussing each criteria of the TG18 in the context of AP.27.8% of biliary AP cases fulfilled TG18 for both AC and CC, 22.5% for CC only and 20.8% for AC only. Antibiotic use was high (77.4%). About 2/3 of the AC/CC cases were mild, around 10% severe. Mortality was below 1% in mild and moderate AC/CC patients, but considerably higher in severe cases (12.8% and 21.2% in AC and CC). ERCP was performed in 89.3% of AC cases, common bile duct stones were found in 41.1%.Around 70% of biliary AP patients fulfilled the TG18 for AC/CC, associated with a high rate of antibiotic use. Mortality in presumed mild or moderate AC/CC is low. Each of the laboratory and clinical criteria are commonly fulfilled in biliary AP, single imaging findings are also unspecific-AP specific diagnostic criteria are needed, as the prevalence of AC/CC are likely greatly overestimated. Randomized trials testing antibiotic use are also warranted. LA - English DB - MTMT ER - TY - JOUR AU - Gál, Eleonóra AU - Menyhárt, I AU - Veréb, Z AU - Kemény, L AU - Tiszlavicz, L AU - Czakó, László AU - Takács, Tamás AU - Hegyi, P AU - Venglovecz, Viktória TI - Importance of MUC17 in the bile-induced pancreatic cancer progression JF - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE J2 - CENT EUR J GASTRO HEPATOL VL - 9 PY - 2023 IS - Suppl 1 SP - 79 EP - 79 PG - 1 SN - 2415-9107 UR - https://m2.mtmt.hu/api/publication/34053506 ID - 34053506 LA - English DB - MTMT ER - TY - JOUR AU - Turcsiné Czapári, Dóra AU - Váradi, Alex AU - Borbásné Farkas, Kornélia AU - Nyári, Gergely Róbert AU - Márta, Katalin AU - Váncsa, Szilárd AU - Nagy, Rita AU - Teutsch, Brigitta AU - Bunduc, Stefania AU - Erőss, Bálint Mihály AU - Czakó, László AU - Vincze, Áron AU - Izbéki, Ferenc AU - Papp, Mária AU - Merkely, Béla Péter AU - Szentesi, Andrea Ildikó AU - Hegyi, Péter ED - Péter, Jenő Hegyi / Collaborator ED - Andrea, Párniczky / Collaborator ED - Mária, Földi / Collaborator ED - Klementina, Ocskay / Collaborator ED - Márk, Félix Juhász / Collaborator ED - Imrei, Marcell / Collaborator ED - Szabolcs, Kiss / Collaborator ED - Alexandra, Mikó / Collaborator ED - Szilárd, Gódi / Collaborator ED - Judit, Bajor / Collaborator ED - Roland, Hágendorn / Collaborator ED - Patrícia, Sarlós / Collaborator ED - Imre, Szabó / Collaborator ED - József, Czimmer / Collaborator ED - Nándor, Faluhelyi / Collaborator ED - Péter, Kanizsai / Collaborator ED - Attila, Miseta / Collaborator ED - Tamás, Nagy / Collaborator ED - László, Gajdán / Collaborator ED - Adrienn, Halász / Collaborator ED - Németh, Balázs / Collaborator ED - Kui, Balázs / Collaborator ED - Illés, Dóra / Collaborator ED - Takács, Tamás / Collaborator ED - Tiszlavicz, László / Collaborator ED - Oláh, Orsolya / Collaborator ED - Radics, Bence / Collaborator ED - Vitális, Zsuzsanna / Collaborator ED - József, Hamvas / Collaborator ED - Márta, Varga / Collaborator ED - Barnabás, Bod / Collaborator ED - János, Novák / Collaborator ED - Pál, Maurovich-Horváth / Collaborator ED - Doros, Attila / Collaborator ED - Pál, Ákos Deák / Collaborator ED - Varga, Csaba / Collaborator ED - Szabolcs, Gaál / Collaborator ED - László, Zubek / Collaborator ED - János, Gál / Collaborator ED - Zsolt, Molnár / Collaborator ED - Tamás, Tornai / Collaborator ED - Balázs, Lázár / Collaborator ED - Tamás, Hussein / Collaborator ED - Beáta, Kovács / Collaborator ED - Anna, Németh / Collaborator ED - Tarján, Dorottya / Collaborator ED - Lipp, Mónika Bernadett / Collaborator ED - Orsolya, Urbán / Collaborator ED - Simon, Tóth / Collaborator ED - Dániel, Söti / Collaborator ED - Dávid, Becker / Collaborator TI - Detailed characteristics of post-discharge mortality in acute pancreatitis JF - GASTROENTEROLOGY J2 - GASTROENTEROLOGY VL - 165 PY - 2023 IS - 3 SP - 682 EP - 695 PG - 14 SN - 0016-5085 DO - 10.1053/j.gastro.2023.05.028 UR - https://m2.mtmt.hu/api/publication/33864451 ID - 33864451 N1 - * Megosztott szerzőség AB - The in-hospital survival of patients suffering from acute pancreatitis (AP) is 95-98%. However, there is growing evidence that patients discharged after AP may be at risk of serious morbidity and mortality. Here, we aimed to investigate the risk, causes, and predictors of the most severe consequence of the post-AP period: mortality.2,613, well-characterized patients from twenty-five centers were collected and followed by the Hungarian Pancreatic Study Group between 2012 and 2021. A general and a hospital-based population was used as the control group.After an AP episode patients have an approximately three-fold higher incidence rate of mortality than the general population (0.0404vs.0.0130 person-years). First-year mortality after discharge was almost double than in-hospital mortality (5.5%vs.3.5%), with 3.0% occurring in the first 90-day period. Age, comorbidities, and severity were the most significant independent risk factors for death following AP. Furthermore, multivariate analysis identified creatinine, glucose, and pleural fluid on admission as independent risk factors associated with post-discharge mortality. In the first 90-day period, cardiac failure and AP-related sepsis were among the main causes of death following discharge, while cancer-related cachexia and non-AP-related infection were the key causes in the later phase.Almost as many patients in our cohort die in the first 90-day period after discharge as during their hospital stay. Evaluation of cardiovascular status, follow-up of local complications, and cachexia-preventing oncological care should be an essential part of post-AP patient care. Future study protocols in AP must include at least a 90-day follow-up period after discharge. LA - English DB - MTMT ER - TY - JOUR AU - Váncsa, Szilárd AU - Sipos, Zoltán AU - Váradi, Alex AU - Nagy, Rita AU - Ocskay, Klementina AU - Juhász, Márk Félix AU - Márta, Katalin AU - Teutsch, Brigitta AU - Mikó, Alexandra AU - Hegyi, Péter Jenő AU - Vincze, Áron AU - Izbéki, Ferenc AU - Czakó, László AU - Papp, Mária AU - Hamvas, József AU - Varga, Márta AU - Török, Imola AU - Mickevicius, Artautas AU - Erőss, Bálint Mihály AU - Párniczky, Andrea AU - Szentesi, Andrea Ildikó AU - Pár, Gabriella AU - Hegyi, Péter ED - Imrei, Marcell / Collaborator ED - Földi, Mária / Collaborator ED - Miklós, Emőke / Collaborator ED - Gódi, Szilárd / Collaborator ED - Hágendorn, Roland / Collaborator ED - Sarlós, Patricia / Collaborator ED - Bajor, Judit / Collaborator ED - Szabó, Imre / Collaborator ED - Czimmer, József / Collaborator ED - Faluhelyi, Nándor / Collaborator ED - Farkas, Orsolya / Collaborator ED - Kanizsai, Péter / Collaborator ED - Nagy, Tamás / Collaborator ED - Németh, Balázs / Collaborator ED - Kui, Balázs / Collaborator ED - Illés, Dóra / Collaborator ED - Takács, Tamás / Collaborator ED - Gajdán, László / Collaborator ED - Vitális, Zsuzsanna / Collaborator ED - Bod, Barnabás / Collaborator ED - Novák, János / Collaborator ED - Macarie, Melania / Collaborator ED - Maurovich-Horvat, Pál / Collaborator ED - Doros, Attila / Collaborator ED - Deák, Pál Ákos / Collaborator ED - Varga, Csaba / Collaborator ED - Gaál, Szabolcs / Collaborator ED - Zubek, László / Collaborator ED - Gál, János / Collaborator ED - Patai, Árpád / Collaborator ED - Tornai, Tamás / Collaborator ED - Lázár, Balázs / Collaborator ED - Hussein, Tamás / Collaborator ED - Kovács, Beáta / Collaborator ED - Tarján, Dorottya / Collaborator ED - Lipp, Mónika Bernadett / Collaborator ED - Urbán, Orsolya / Collaborator ED - Emese, Fürst / Collaborator ED - Tari, Edina / Collaborator TI - Metabolic-associated fatty liver disease is associated with acute pancreatitis with more severe course : Post hoc analysis of a prospectively collected international registry JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - 4 SP - 371 EP - 382 PG - 12 SN - 2050-6406 DO - 10.1002/ueg2.12389 UR - https://m2.mtmt.hu/api/publication/33761635 ID - 33761635 N1 - Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary Centre for Translational Medicine, Semmelweis University, Budapest, Hungary Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary Institute of Bioanalysis, Medical School, University of Pécs, Pécs, Hungary Department of Metagenomics, University of Debrecen, Debrecen, Hungary Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary Heim Pál National Pediatric Institute, Budapest, Hungary Department of Medical Genetics, Medical School, University of Pécs, Pécs, Hungary Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary Szent György University Teaching Hospital of Fejér County, Székesfehérvár, Hungary Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary Department of Gastroenterology, Institute of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Peterfy Hospital, Budapest, Hungary Department of Gastroenterology, BMKK Dr. Réthy Pál Hospital, Békéscsaba, Hungary County Emergency Clinical Hospital of Targu Mures - Gastroenterology and George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania Clinics of Abdominal Surgery, Nephrology and Gastroenterology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania Translational Pancreatology Research Group, Interdisciplinary Centre of Excellence for Research Development and Innovation University of Szeged, Szeged, Hungary Cited By :1 Export Date: 1 October 2023 Correspondence Address: Hegyi, P.Szigeti Street 12, Hungary; email: hegyi2009@gmail.com AB - Non-alcoholic fatty liver disease (NAFLD) is a proven risk factor for acute pancreatitis (AP). However, NAFLD has recently been redefined as metabolic-associated fatty liver disease (MAFLD). In this post hoc analysis, we quantified the effect of MAFLD on the outcomes of AP.We identified our patients from the multicentric, prospective International Acute Pancreatitis Registry of the Hungarian Pancreatic Study Group. Next, we compared AP patients with and without MAFLD and the individual components of MAFLD regarding in-hospital mortality and AP severity based on the revised Atlanta classification. Lastly, we calculated odds ratios (ORs) with 95% confidence intervals (CIs) using multivariate logistic regression analysis.MAFLD had a high prevalence in AP, 39% (801/2053). MAFLD increased the odds of moderate-to-severe AP (OR = 1.43, CI: 1.09-1.89). However, the odds of in-hospital mortality (OR = 0.89, CI: 0.42-1.89) and severe AP (OR = 1.70, CI: 0.97-3.01) were not higher in the MAFLD group. Out of the three diagnostic criteria of MAFLD, the highest odds of severe AP was in the group based on metabolic risk abnormalities (OR = 2.68, CI: 1.39-5.09). In addition, the presence of one, two, and three diagnostic criteria dose-dependently increased the odds of moderate-to-severe AP (OR = 1.23, CI: 0.88-1.70, OR = 1.38, CI: 0.93-2.04, and OR = 3.04, CI: 1.63-5.70, respectively) and severe AP (OR = 1.13, CI: 0.54-2.27, OR = 2.08, CI: 0.97-4.35, and OR = 4.76, CI: 1.50-15.4, respectively). Furthermore, in patients with alcohol abuse and aged ≥60 years, the effect of MAFLD became insignificant.MAFLD is associated with AP severity, which varies based on the components of its diagnostic criteria. Furthermore, MAFLD shows a dose-dependent effect on the outcomes of AP. LA - English DB - MTMT ER - TY - JOUR AU - Szabó, Á. AU - Feró, E. AU - Gyömbér, E. AU - Göncz, M. AU - Soós, E. AU - Czakó, László AU - Takács, Tamás AU - Bor, Renáta AU - Szepes, Zoltán TI - Az antibakteriális oldattal történő szájöblítés hatása a post-ERCP-s cholangitis kialakulására JF - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE J2 - CENT EUR J GASTRO HEPATOL VL - 8 PY - 2022 IS - Suppl. 1 SP - 101 EP - 101 PG - 1 SN - 2415-9107 UR - https://m2.mtmt.hu/api/publication/34014741 ID - 34014741 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Gieszinger, G. AU - Tajti, M. AU - Karamya, Zain Alabedeen AU - Szepes, Zoltán AU - Takács, Tamás AU - Kui, Balázs AU - Illés, Dóra AU - Ivány, Emese AU - Czakó, László TI - Endoscopic papillectomy for ampullary adenoma: are we good enough? JF - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE J2 - CENT EUR J GASTRO HEPATOL VL - 8 PY - 2022 IS - Suppl. 1 SP - 78 EP - 78 PG - 1 SN - 2415-9107 UR - https://m2.mtmt.hu/api/publication/34013125 ID - 34013125 LA - English DB - MTMT ER - TY - JOUR AU - Németh, Balázs AU - Madarász, R AU - Nagy, A AU - Sándor, M AU - Stefanovics, R AU - Karamya, Z AU - Takács, Tamás AU - Farkas, G AU - Izbéki, F AU - Czakó, László AU - Szmola, R AU - Gervain, J AU - Gódi, S AU - Szentesi, A AU - Szücs, Á AU - Sahin-Tóth, M AU - Hegyi, P TI - Mutations in the 5’ upstream region of chymotrypsinogen C gene are not associated with chronic pancreatitis JF - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE J2 - CENT EUR J GASTRO HEPATOL VL - 8 PY - 2022 IS - Suppl. 1 SP - 93 EP - 94 PG - 2 SN - 2415-9107 UR - https://m2.mtmt.hu/api/publication/32991767 ID - 32991767 LA - English DB - MTMT ER - TY - JOUR AU - Pesei, Z AU - Hegede, R AU - Németh, Balázs AU - Takács, Tamás AU - Szentesi, A AU - Farkas, G AU - Czakó, László AU - Hegyi, P AU - Hegyi, E TI - A TRPV6 gén mutációinak szerepe krónikus hasnyálmirigy-gyulladásban JF - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE J2 - CENT EUR J GASTRO HEPATOL VL - 8 PY - 2022 IS - 1 SP - 98 SN - 2415-9107 UR - https://m2.mtmt.hu/api/publication/32991670 ID - 32991670 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Gál, Eleonóra AU - Veréb, Zoltán AU - Rakk, Dávid AU - Szekeres, András AU - Becskeházi, Eszter AU - Tiszlavicz, László AU - Czakó, László AU - Takács, Tamás AU - Hegyi, P AU - Venglovecz, Viktória TI - The effect of bile on pancreatic cancer, the importance of mucins JF - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE J2 - CENT EUR J GASTRO HEPATOL VL - 8 PY - 2022 IS - Suppl. 1 SP - 77 EP - 77 PG - 1 SN - 2415-9107 UR - https://m2.mtmt.hu/api/publication/32843481 ID - 32843481 LA - English DB - MTMT ER -